API Trading Company Dubai — Sourcing Active Pharmaceutical Ingredients for Asian Markets

API Trading — The Commercial Core of What We Do

Active pharmaceutical ingredients are the most technically demanding and commercially significant category Equihealth trades in. The quality of an API determines the quality of the finished drug. The reliability of the supply chain determines whether a manufacturer can keep its production lines running.

Equihealth FZCO is an API trading company based in Dubai Commercity, UAE. We source bulk active pharmaceutical ingredients from qualified manufacturers in India, China, and the European Union, and supply them to pharmaceutical formulation companies across South Asia, Southeast Asia, and other international markets.

What Active Pharmaceutical Ingredients Are

An active pharmaceutical ingredient is the component in a drug product that produces the intended therapeutic effect. Every finished pharmaceutical — a tablet, capsule, injectable, topical preparation, or liquid dosage form — contains at least one API. The formulation company that manufactures the finished product sources the API separately from a specialist manufacturer, and combines it with excipients and other raw materials to produce the final dosage form.

Most formulation companies do not manufacture their own APIs. They source them from API producers, either directly or through trading intermediaries. Equihealth operates as that intermediary for formulation companies across Asia who need reliable, quality-documented access to APIs from established manufacturers in India, China, and Europe.

Where We Source From

India

India is the largest exporter of generic APIs in the world. Indian API manufacturers supply a significant share of the global generic pharmaceutical market across a wide range of therapeutic categories. Equihealth's sourcing network includes established relationships with API manufacturers in India whose production facilities meet the quality standards required by pharmaceutical buyers in our target markets.

China

China is the other dominant force in global API production, particularly in the manufacturing of chemical intermediates and bulk APIs used in generic drug formulation. Equihealth sources from Chinese manufacturers for buyers whose specifications and regulatory requirements are met by Chinese-origin materials.

European Union

EU-origin APIs are required by some formulation manufacturers whose end-product registrations specify European-origin materials, or whose target markets carry regulatory preferences for EU-sourced active ingredients. Equihealth sources from manufacturers in Italy and France for buyers where EU origin is a commercial or regulatory requirement.

Who We Supply

Our primary buyers for APIs are pharmaceutical formulation manufacturers — companies that process active pharmaceutical ingredients into finished dosage forms for commercial distribution. These manufacturers operate across Bangladesh, Pakistan, Singapore, Indonesia, Vietnam, Malaysia, Thailand, Hong Kong, China, and India.
We also supply qualified chemical processing companies that use pharmaceutical-grade APIs and intermediates as inputs in their own production processes, where the regulatory framework of the destination market permits this.

The API Trading Process

API trading involves more than matching a buyer's specification to a supplier's product list. It requires understanding the regulatory context of the destination market, the quality documentation requirements of the buying manufacturer, the incoterms and logistics considerations for the specific origin-destination pair, and the financial and payment structure that works for both sides.
Equihealth manages this through its Bill-to Ship-to trading model. The supplier ships the API directly to the formulation manufacturer. Equihealth manages the commercial relationship, the invoicing, and the documentation from Dubai. The formulation manufacturer receives the goods and pays Equihealth. Equihealth settles with the supplier.
How the Bill-to Ship-to Model Works

Quality and Documentation Standards

API quality is not negotiable in pharmaceutical manufacturing. Equihealth works with API manufacturers whose production facilities and quality management systems meet the standards applicable to the destination markets we supply. This includes compliance with Good Manufacturing Practice requirements, accurate Certificate of Analysis documentation, and full traceability of the API from manufacturing batch to point of delivery.
Every transaction Equihealth manages includes the documentation chain a formulation manufacturer needs for its own quality records and regulatory submissions.

Why Formulation Manufacturers Work With an API Trading Company

Working through a trading intermediary like Equihealth makes sense in specific circumstances: when direct relationships are not yet established; when payment and trade finance across jurisdictions are complex; when a single sourcing partner covering multiple APIs from both India and China reduces administrative load; or when a manufacturer is entering a new product line and needs access to a qualified supplier network without the lead time of direct qualification.

Why API Manufacturers Work With Equihealth

For API manufacturers in India, China, and Europe looking to reach formulation companies in South and Southeast Asia, Equihealth offers an established commercial network of qualified buyers. Formulation manufacturers in Bangladesh, Pakistan, Indonesia, Vietnam, and other markets Equihealth serves are active buyers of APIs — producing generic pharmaceuticals at scale for their home markets and for export.
Equihealth provides API manufacturers with a structured, financially sound trading partner that handles the commercial and documentary complexity of cross-border trading and settles transactions through established UAE banking channels.
For Suppliers

Geographic Reach for API Distribution

Equihealth's current API distribution covers South Asia (Bangladesh, Pakistan, India), Southeast Asia (Singapore, Indonesia, Vietnam, Malaysia, Thailand), East Asia (China, Hong Kong), and the Middle East and North Africa (Egypt). Expansion into European and US regulated markets is planned for a subsequent phase, once current market coverage is established and operating.
See Our Full Market Coverage

Starting a Commercial Conversation

Whether you are a pharmaceutical formulation manufacturer looking for a reliable API sourcing partner or an API manufacturer looking for a distribution channel into Asian markets, the right starting point is a direct conversation. Tell us the API or APIs you are sourcing, the specification, the volume, the destination market, and your timeline. We will tell you whether we can help and what the next steps look like.
Contact Equihealth
For Manufacturers

Frequently Asked Questions

An API trading company is a commercial intermediary that sources active pharmaceutical ingredients from manufacturers and supplies them to formulation companies or other qualified buyers. Unlike a broker, a trading company takes commercial ownership of the transaction, issues its own invoices, and manages the full documentary and payment chain between supplier and buyer.
Equihealth sources active pharmaceutical ingredients from manufacturers in India, China, and the European Union — specifically Italy and France for EU-origin materials. India and China are the dominant global producers of generic APIs.
Our current API distribution targets cover Bangladesh, Pakistan, Singapore, Indonesia, Vietnam, Malaysia, Thailand, Hong Kong, China, India, and Egypt — the primary generic pharmaceutical manufacturing economies in South and Southeast Asia.
Equihealth does not currently operate a warehousing function. APIs are shipped directly from the manufacturer to the formulation company under our Bill-to Ship-to model.
Yes. Our product coverage is not limited to a published list. Contact us with the compound, specification, and volume, and we will assess whether we can source it through our network.